Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference
Allurion Technologies (NYSE: ALUR) presented significant data at Obesity Week 2024, showcasing results from their largest real-world study involving 19,428 patients across 72 countries. The study demonstrated an average weight reduction of 12.2% after four months using the Allurion Program. Additionally, a second study revealed that patients who previously had unsuccessful results with liraglutide achieved an average 17.6% weight reduction after four months on the Allurion Program. This group included patients where 55% had no weight loss and 45% had less than 5% weight loss with GLP-1 medications.
Allurion Technologies (NYSE: ALUR) ha presentato dati significativi durante l'Obesity Week 2024, mostrando i risultati del loro studio reale più grande che ha coinvolto 19.428 pazienti in 72 paesi. Lo studio ha dimostrato una riduzione media del peso del 12,2% dopo quattro mesi utilizzando il Programma Allurion. Inoltre, un secondo studio ha rivelato che i pazienti che in precedenza avevano ottenuto risultati negativi con liraglutide hanno raggiunto una riduzione media del peso del 17,6% dopo quattro mesi con il Programma Allurion. Questo gruppo includeva pazienti in cui il 55% non aveva perso peso e il 45% aveva avuto una perdita di peso inferiore al 5% con i farmaci GLP-1.
Allurion Technologies (NYSE: ALUR) presentó datos significativos en la Semana de la Obesidad 2024, mostrando los resultados de su estudio del mundo real más grande, que involucró a 19,428 pacientes en 72 países. El estudio demostró una reducción media de peso del 12.2% después de cuatro meses utilizando el Programa Allurion. Además, un segundo estudio reveló que los pacientes que anteriormente habían tenido resultados insatisfactorios con liraglutida lograron una reducción media de peso del 17.6% después de cuatro meses en el Programa Allurion. Este grupo incluía pacientes en los que el 55% no había perdido peso y el 45% había tenido una pérdida de peso de menos del 5% con medicamentos GLP-1.
Allurion Technologies (NYSE: ALUR)는 2024 비만 주간에서 중요한 데이터를 발표하며 72개국의 19,428명 환자를 대상으로 한 최대 규모의 실제 연구 결과를 선보였습니다. 이 연구는 Allurion 프로그램을 사용한 후 4개월 동안 평균 12.2%의 체중 감소를 보여주었습니다. 또한, 두 번째 연구에서 리라글루타이드로 이전에 성공적인 결과를 얻지 못한 환자들이 Allurion 프로그램을 통해 4개월 후 평균 17.6%의 체중 감소를 달성했다고 밝혔습니다. 이 그룹은 55%가 체중 감소가 없었고 45%가 GLP-1 약물로 5% 미만의 체중 감소를 경험한 환자들로 구성되었습니다.
Allurion Technologies (NYSE: ALUR) a présenté des données significatives lors de la Semaine de l'Obésité 2024, mettant en avant les résultats de leur plus grande étude en conditions réelles impliquant 19 428 patients dans 72 pays. L'étude a révélé une réduction moyenne de poids de 12,2% après quatre mois d'utilisation du Programme Allurion. De plus, une deuxième étude a révélé que les patients qui avaient précédemment obtenu des résultats infructueux avec le liraglutide ont atteint une réduction de poids moyenne de 17,6% après quatre mois avec le Programme Allurion. Ce groupe comprenait des patients dont 55% n'avaient pas perdu de poids et 45% avaient moins de 5% de perte de poids avec des médicaments GLP-1.
Allurion Technologies (NYSE: ALUR) präsentierte bedeutende Daten während der Obesity Week 2024 und zeigte die Ergebnisse ihrer größten Real-World-Studie mit 19.428 Patienten aus 72 Ländern. Die Studie zeigte eine durchschnittliche Gewichtsreduktion von 12,2% nach vier Monaten unter Verwendung des Allurion-Programms. Darüber hinaus ergab eine zweite Studie, dass Patienten, die zuvor mit Liraglutid keine erfolgreichen Ergebnisse erzielt hatten, nach vier Monaten im Allurion-Programm eine durchschnittliche 17,6% Gewichtsreduktion erreichten. Diese Gruppe umfasste Patienten, von denen 55% keinen Gewichtsverlust und 45% weniger als 5% Gewichtsverlust mit GLP-1-Medikamenten hatten.
- Large-scale real-world study shows consistent 12.2% average weight reduction across 19,428 patients
- Demonstrated 17.6% weight reduction in patients who failed GLP-1 treatment
- Program shows effectiveness across 72 countries, indicating strong market penetration
- None.
Insights
The real-world data from 19,428 patients across 72 countries demonstrates robust validation of the Allurion Program's effectiveness, showing an average
The second study's findings on GLP-1 non-responders are particularly significant. Patients who failed to achieve meaningful results with liraglutide attained an impressive
These clinical results strengthen Allurion's market position in the competitive weight loss industry. The large-scale real-world evidence spanning 72 countries provides credibility and could accelerate insurance coverage and market adoption. The successful treatment of GLP-1 non-responders is particularly strategic, as it positions Allurion as a complementary rather than competing solution to popular GLP-1s like Wegovy and Ozempic, potentially opening new revenue streams and partnership opportunities.
19,428 patients treated with the Allurion Program across 72 countries lost an average of
The first abstract comprises outcomes data from Allurion’s largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countries treated between 2018 and 2023 with the Allurion Program with results tracked digitally through the Allurion Virtual Care Suite, reveals consistent and significant weight loss outcomes with an average weight reduction of
“While a number of clinical trials have been conducted on intragastric balloons, there has been a persistent lack of large-scale, real-world outcomes data,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “These data demonstrate that the Allurion Program can consistently and repeatedly achieve clinically meaningful weight loss in a vast and diverse population, adding to the data that have already been published on the Allurion Program in over 26 peer-reviewed publications.”
The second abstract reports on outcomes of the Allurion Program for 27 patients previously treated with liraglutide who did not respond to their GLP-1 treatment.
“Clinical studies indicate that, depending on the GLP-1 medication, more than a third of patients do not achieve over
Sources: 1. Gasoyan H, Pfoh ER, Schulte R, Le P, Butsch WS, Rothberg MB. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Netw Open. 2024;7(9):e2433326. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.33326
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104695905/en/
Global Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com
Investor Contact
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com
Source: Allurion Technologies, Inc.
FAQ
What was the average weight loss percentage in Allurion's (ALUR) 2024 real-world study?
How many patients were included in Allurion's (ALUR) largest real-world study presented at Obesity Week 2024?